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New York, NY, USAA B S T R A C TObjective: To compare the efﬁcacy of bazedoxifene and oral
bisphosphonates for the prevention of nonvertebral fractures (NVFs)
in women with higher risk of postmenopausal osteoporosis (i.e., the
Fracture Risk Assessment Tool [FRAX] score Z 20%), based on
currently available evidence from randomized controlled trials. Meth-
ods: Randomized controlled trials evaluating the NVF relative risk
reduction (RRR) with oral bisphosphonates or bazedoxifene were
identiﬁed by a systematic literature review and combined by means
of a network meta-analysis. A subgroup of patients with a FRAX score
of 20% or more in the bazedoxifene phase III osteoporosis study was
selected as the population of interest on the basis of the bazedoxifene
label. In one analysis (analysis 1), the placebo response of the
subgroup with a FRAX score of 20% or more was the benchmark to
select comparable bisphosphonate trials. Additional analyses
incorporated the aggregate data from the bisphosphonate trials with
all the FRAX subgroups (analysis 2) or with the individual patient
data from the bazedoxifene trial (analysis 3). Results: Nine identiﬁed
bisphosphonate trials (alendronate, ibandronate, risedronate; N ¼ 23,440ee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.01.008
nsen@tufts.edu.
ndence to: Jeroen P. Jansen, Tufts University Schopatients) with a similar placebo response as observed for the subgroup of
high risk patients in the bazedoxifene trial were included in analysis 1.
The results of the network meta-analysis of this study set suggest that
bazedoxifene is expected to have an RRR of 0.43 (95% credible interval
[CrI] 0.19 to 0.72) versus alendronate, 0.58 (95% CrI 0.05–0.81) versus
ibandronate, and 0.39 (95% CrI 0.29 to 0.70) versus risedronate.
Analyses in which treatment effects with bisphosphonates were pro-
jected to a population with a FRAX score of 20% or more with meta-
regression approaches (analysis 2 and analysis 3) provide similar
ﬁndings. Conclusion: Based on an indirect comparison of randomized
trials, bazedoxifene is expected to have at least a comparable RRR of NVF
as alendronate, ibandronate, and risedronate in women with higher risk
of postmenopausal osteoporosis.
Keywords: meta-analysis, osteoporosis, systematic review, treatment
comparisons.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Osteoporosis, characterized by low bone mineral density and
deterioration of bone structure, is primarily present in postme-
nopausal women and is associated with an increased risk of
vertebral, hip, and other nonvertebral fractures [1]. Of the frac-
tures attributed to osteoporosis, approximately 70% occur in
nonvertebral locations, including the hip, forearm, and humerus
[2,3]. These nonvertebral fractures are associated with substantial
mortality and health care costs [4–6].
The most commonly prescribed treatments for osteoporosis
are oral bisphosphonates (e.g., alendronate, risedronate, and
ibandronate). Bazedoxifene, a novel selective estrogen receptor
modulator, is approved in the European Union and in some Asian
countries for the treatment of postmenopausal osteoporosis in
women at an increased risk of fracture [7,8]. Furthermore, in phase
III trials, it has been shown to reduce the risk of nonvertebralfractures in a subgroup of postmenopausal patients with a 10-year
fracture risk at or above 20% as assessed by the Fracture Risk
Assessment Tool (FRAX). The FRAX tool, developed by the World
Health Organization, incorporates clinical risk factors such as age,
body mass index, previous fracture, current smoking status, and
bone mineral density to estimate the 10-year probability of a hip
fracture and the 10-year probability of a major osteoporosis event
(i.e., vertebral, hip, forearm, or shoulder fracture) [9].
To aid evidence-based medical decisions, comparisons of all
available therapies should be available for all populations of
interest. The current evidence base for nonvertebral fracture risk
reduction in osteoporotic women, however, consists of many
randomized controlled trials (RCTs) that are placebo controlled
and do not provide head-to-head direct comparisons. Further-
more, the bisphosphonate RCTs do not present subgroup results
according to the FRAX score. In the absence of an RCT comparing
all relevant therapies, an indirect treatment comparison byociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ol of Medicine, Boston, MA 02111.
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is a valid alternative to provide relevant comparative evidence
when there are no systematic differences across comparisons
related to the treatment effects.
The objective of this study was to compare the reduction in
nonvertebral fracture risk with bazedoxifene relative to oral
bisphosphonates for those patients who are at a higher risk of a
clinical osteoporotic fracture (i.e., with a FRAX score of at least 20%).Methods
Identiﬁcation and Selection of Studies
A systematic literature search was performed to identify relevant
RCTs published in English from 1990 to November 2011. MED-
LINE, Embase, and Cochrane Library Clinical Trials databases
were searched according to predeﬁned search strategy with
terms relevant to osteoporosis, alendronate, ibandronate, risedr-
onate, bazedoxifene, and RCTs. A hand search of references was
also conducted to identify any missing trials. Each identiﬁed
study was evaluated against the following predeﬁned criteria: Population of interest: Postmenopausal women with primary
osteoporosis; Interventions: Oral bisphosphonates (alendronate 5 and 10 mg,
ibandronate 2.5 mg, risedronate 5 mg) and bazedoxifene (20
and 40 mg); Comparators: Placebo or one of the regimes described under
interventions. Comparisons of different dosages of the same
intervention only were excluded because such comparisons
have limited ability to strengthen estimates of the compar-
isons of interest. Comparison of the same interventions with
different background treatments were also excluded to limit
issues of comparability of patients; Outcomes: Incidence of nonvertebral fractures; and
 Study Design: RCTs. Nonexperimental studies (e.g., cohort,
case-control, cross-sectional studies) as well as (systematic)
literature reviews, commentaries, and other meta-analyses
were excluded.
The excluded publications that did not meet the above
selection criteria were considered out of scope.
Data Extraction and Quality Assessment
For each identiﬁed study that met the selection criteria, data on
study design, patient characteristics, interventions, and the
number of patients experiencing a nonvertebral fracture during
the trial were extracted. For the bazedoxifene trial, subgroup data
and individual patient-level data were available and obtained for
both placebo and bazedoxifene trial arms.
The quality of each trial was assessed using the National
Institute of Health and Care Excellence checklist for RCTs, which
consists of seven questions regarding randomization, allocation
concealment, similarity of the groups in terms of prognostic
factors, blinding, dropouts and imbalances between groups, out-
come reporting, and intention to treat methodology [10]. The
results of the quality assessment were not explicitly used in the
analyses but provide additional information to determine the
quality of the evidence base when interpreting the results.
Analyses
Treatment effects of the different studies were synthesized and
indirectly compared by means of an NMA [11–14].
The NMAs were performed within a Bayesian framework and
involve data, a likelihood distribution, a model with parameters,and prior distributions for these parameters [15]. The model
relates the data from the individual studies to basic parameters
reﬂecting the (pooled) relative treatment effect of each interven-
tion compared with an overall reference treatment, namely,
placebo. Based on these basic parameters, the relative efﬁcacy
between bazedoxifene and each of the competing bisphospho-
nates was calculated. For nonvertebral fractures, a logistic
regression model with a binomial likelihood distribution
was used.
The validity of the NMA depends on the comparability or
exchangeability of patients across trials. For this analysis, a
potential challenge was assessing the differences across patients
in terms of baseline fracture risk. For an indirect comparison of
bazedoxifene with bisphosphonates in the higher risk population
of interest (FRAX score Z 20%), it is ideal to have data on
treatment effects for these interventions in this population.
Although individual patient data (IPD) including FRAX scores
were available for the bazedoxifene trial and the relationship
between FRAX scores and treatment effects in the subgroup of
patients at or above a certain FRAX score threshold could be
estimated there, results only with aggregated data (AD) (i.e., the
published ﬁndings) were available for the bisphosphonate trials,
with no information on treatment effects by FRAX subgroup.
Because of the lack of FRAX data for the subjects in the
bisphosphonate studies, it is difﬁcult to assess comparability of
patients across the bisphosphonate and bazedoxifene trials
based on the FRAX assessment. To address this issue, the
incidence of nonvertebral fracture in the placebo arm was used
as an assessment of baseline fracture risk. Given the available
evidence, multiple analyses were conducted to obtain treatment
effect estimates of bazedoxifene relative to oral bisphosphonates
for the population with FRAX scores of 20% or more, namely: Comparison based on AD of bisphosphonates and FRAX score of 20%
or more subgroup for bazedoxifene: NMA based on AD in which
only those bisphosphonate studies were selected that showed
a similar (i.e., not statistically signiﬁcantly different at the 0.05
level) nonvertebral fracture incidence in the placebo arm as
did the placebo response of the subgroup with a FRAX score of
20% or more in the bazedoxifene trial. Meta-regression based on AD of bisphosphonates and all FRAX
subgroups for bazedoxifene: NMA based on AD for all FRAX
subgroups of the bazedoxifene trial and all AD for the
published bisphosphonate trials. The model includes covari-
ates that capture the effect of placebo response on the treat-
ment effects (i.e., log odds ratio [OR] of nonvertebral fractures)
with oral bisphosphonates and bazedoxifene relative to pla-
cebo. The relationship between baseline risk and treatment
effects was estimated for each treatment separately but
assumed exchangeable. The advantage of this analysis over
analysis 1 is that all studies and all subgroups were used. The
treatment effects for all interventions indirectly compared
were centered at a placebo response for nonvertebral fractures
corresponding to the subgroup with a FRAX score of 20% or
more in the bazedoxifene trial. Meta-regression based on AD of bisphosphonates and IPD for
bazedoxifene: NMA based on IPD for the bazedoxifene trial
and AD for the published bisphosphonate studies. The
advantage of an analysis with IPD is that the relationship
between baseline risk and treatment effect with bazedoxifene
can be estimated without relying on a linear association while
still using all data. Although a model with a linear relation-
ship between baseline risk and treatment effect was tested
(results not presented), a model with a quadratic relationship
provided a better ﬁt to the IPD and was used for this analysis.
The covariate in the model captures the effect of a 10-year
baseline fracture risk on the treatment effects (i.e., log OR of
F
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doxifene relative to placebo. The FRAX score reﬂects the 10-
year fracture risk available for individuals in the bazedoxifene
trial. For the bisphosphonate trials, the placebo response over
the follow-up of the trial (e.g., 1–4 years) was transformed to a
10-year (nonvertebral fracture) risk as well. The treatment
effects for all interventions indirectly compared were centered
at a 10-year fracture risk of 20% or more. The models are
presented in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.01.008.
For each analysis, ﬁxed- and random-effects models were
compared regarding the goodness of ﬁt to the data, using the
deviance information criterion. The random-effects model
resulted in a lower deviance information criterion, and hence
was considered appropriate for the synthesis of the available
evidence.
To avoid inﬂuence of the prior distributions required for
Bayesian analyses on the results, noninformative prior distribu-
tions were used. Prior distributions of the treatment effects were
normal distributions with mean 0 and a variance of 10,000. A
uniform distribution with a (noninformative) range of 0 to 2 was
used for the prior distribution of heterogeneity needed for the
random-effects analyses. WinBugs statistical software was used
for the analyses [16].
The results of the NMA are the treatment effects of each
treatment versus placebo presented as an OR of a nonvertebral
fracture. From the ORs, the risk of a nonvertebral fracture for
each treatment can be calculated using the average modeledig. 1 – Flow diagram summarizing results of study identiﬁcation
ontrolled trials.placebo risk of a fracture for the population of interest and
transformed to other effect measures such as the relative risk
reduction (RRR) [1–relative risk], which may be a more intuitive
measure of effectiveness. Summary statistics are presented for
treatment effects, that is, OR and RRR, and expected result
(probability of nonvertebral fracture) with corresponding 95%
credible intervals (95% CrI) reﬂecting the range of true underlying
effects with 95% probability. The probability that a certain treat-
ment provides greatest RRR out of all those compared was
calculated (i.e., probability of being best treatment), as well as
the probability that each treatment is better than a certain
comparator, which are based on the posterior distribution of
the treatment effects.Results
Study Identiﬁcation
In Figure 1, the results of the literature search are presented. The
database search identiﬁed 1462 abstracts. After the duplicates
were removed from these databases (n ¼ 488), 974 potentially
relevant publications were identiﬁed. The abstract screening
excluded 882 potentially relevant publications that did not meet
selection criteria. The full-text review of the 92 remaining
publications excluded 82 studies for reasons including outcomes
(n ¼ 48), study design (15), population (10), unable to retrieve full
text (4), comparison (2), non-English language (2), and interven-
tion dose (1). In addition, a hand search of references identiﬁed a
further 2 RCTs to be included in the analyses. Overall, 12 full-textand selection. pop., population; RCTs, randomized
Table 1 – Study and patient characteristics.
Author, year Trial Active
drug
Dosing Treatment
duration (y)
Summary inclusion/exclusion Calcium/
vitamin D
No. of centers/
countries
Bone et al. (1997)
[19]
Alendronate Elderly
Osteoporosis
Study
ALEN 5 mg/d for 2 y 2 Women (age 60–85 y) with low bone
mass
500 mg/NR 15/United States
Liberman et al.
(1995) [20]
Alendronate Phase
III Osteoporosis
Treatment Study
ALEN 5 mg/d or 10 mg/
d for 3 y; or 20
mg/d for 2 y then
5 mg/d for 1 y
3 Postmenopausal (Z5 y) women (age
45–80 y) with low bone mass
500 mg/NR NR/Australia, Canada,
Europe, Israel, Mexico,
New Zealand, South
America, United
States
Chesnut et al.
(2004) [21],
Chesnut et al.
2005 [22]
BONE IBAN 2.5 mg/d for 3 y 3 Postmenopausal (Z5 y) women (age
55–80 y) with low bone mass and
one to four vertebral fractures
500 mg/400 IU 73/Europe and United
States
Black et al. (1996)
[23]
FIT I (Vertebral
Fractures)
ALEN 5 mg/d for 2 y
then 10 mg/d for
1 y
3 Postmenopausal (Z2 y) women (age
55–81 y) with low bone mass and
one or more vertebral fracture
500 mg/ 250 IU 11/United States
Cummings et al.
(1998) [24]
FIT II (Clinical
Fractures)
ALEN 5 mg/d for 2 y
then 10 mg/d for
2 y
4 Postmenopausal (Z2 y) women (age
55–80 y) with low bone mass and no
vertebral fractures
500 mg/250 IU 11/United States
Pols et al. (1999)
[25]
FOSIT ALEN 10 mg/d for 1 y 1 Postmenopausal (Z3 y) women (age
r85 y) with low bone bass
500 mg/NR 153/Europe, Latin
America, Australia,
Canada, South Africa,
China
McClung et al.
(2001) [26]
HIP RISED 2.5 mg/d or 5 mg/
d for 3 y
3 Postmenopausal women (age 70–79 y)
with low bone mass or
postmenopausal women (age Z80
y) with low bone mass with at least
one nonskeletal risk factor for hip
fracture
1000 mg/up to
500 IU
183/North America,
Europe, New Zealand,
Australia
Reginster et al.
(2000) [27]
VERT-MN RISED 5 mg/d for 3 y 3 Postmenopausal (Z5 y) women (age
r85 y) with two or more vertebral
fractures
1000 mg/up to
500 IU
80/Europe and
Australia
Harris et al.
(1999) [28]
VERT-NA RISED 5 mg/d for 3 y 3 Postmenopausal (Z5 y) women (age
r85 y) with two or more vertebral
fractures or one vertebral fracture
and low lumbar-spine BMD
1000 mg/up to
500 IU
110/North America
Fogelman et al.
(2000) [29]
– RISED 5 mg/d for 2 y 2 Postmenopausal (Z1 y) women (age
r80 y) with low bone mass
1000 mg/NR 13/France, United
Kingdom,
Netherlands, Belgium,
Germany
Silverman et al.
(2008) [17]
– BAZ 20 mg/d or 40
mg/d for 3 y
3 Postmenopausal (Z2 y) women (age
55–85 y) with low bone mass
Up to 1200 mg/
400–800 IU
206/Asia-Paciﬁc
countries, Canada,
Europe, Latin
America, South Africa,
United States
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Table 1 – continued
Author, year Trial Number
randomized
Age (y)
(mean)
Years since
menopause
(mean)
Hologic mean lumbar spine
BMD (mean) [T score]
Patients with
baseline fractures
(%)
Nonvertebral fractures
placebo, n/N (%) [annual rate]
Nonvertebral fractures
active, n/N (%) [annual rate]
Bone et al.
(1997) [19]
Alendronate Elderly
Osteoporosis Study
184 71 24 0.72 [NR] 36 16/91 (17.6) [0.09] 9/93 (9.7) [0.05]
Liberman
et al. (1995)
[20]
Alendronate Phase III
Osteoporosis Treatment
Study
994 64 16 0.71 [NR] 21 38/397 (9.6) [0.03] 45/597 (7.5) [0.03]
Chesnut et al.
(2004) [21]
BONE 1964 69 21 NR [2.8] 94 80/975 (8.2) [0.03] 89/977 (9.1) [0.03]
Black et al.
(1996) [23]
FIT I (Vertebral Fractures) 2027 71 NR 0.79 [NR] 100 148/1005 (14.7) [0.05] 122/1022 (11.9) [0.04]
Cummings
et al. (1998)
[24]
FIT II (Clinical Fractures) 4432 68 NR 0.84 [NR] 0 294/2218 (13.3) [0.03] 261/2214 (11.8) [0.03]
Pols et al.
(1999) [25]
FOSIT 1908 63 16 0.72 [NR] NR 37/958 (3.9) [0.04] 19/950 (2.0) [0.02]
McClung et al.
(2001) [26]
HIP 9331 78 32 NR [NR] 41 351/3134 (11.2) [0.04] 583/6197 (9.4) [0.03]
Reginster
et al. (2000)
[27]
VERT-MN 816 71 25 0.79 [2.8] 98 51/406 (12.6) [0.04] 36/406 (8.9) [0.03]
Harris et al.
(1999) [28]
VERT-NA 1641 69 24 0.83 [2.4] 80 52/815 (6.4) [0.02] 33/812 (4.1) [0.01]
Fogelman
et al. (2000)
[29]
– 359 64 17 0.74 [2.9] 31 13/180 (7.2) [0.04] 7/177 (4.0) [0.02]
Silverman
et al. (2008)
[17]
– 5643 66 20 NR [2.4] 56 99/1885 (5.3) [0.02] 174/3758 (4.6) [0.02]
ALEN, alendronate; BAZ, bazedoxifene; BMD, bone mineral density; BONE, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe; FIT, Fracture Intervention Trial;
FOSIT, Fosomax International Trial; HIP, Hip Intervention Program; IBAN, ibandronate; NR, not reported; RISED, risedronate; VERT, Vertebral Efﬁcacy with Risedronate Therapy; VERT-MN,
VERT-Multinational; VERT-NA, VERT-North America.
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Unpublished subgroup data according to the FRAX score and the
IPD for the bazedoxifene trial were also provided [17].A
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Table 1 provides a summary of the included trials, which were
of similar quality. All studies were multicenter, double-blind,
placebo-controlled RCTs and, in addition to the study interven-
tions, patients were provided with at least 500 mg of a
calcium supplement per day and some patients also received
vitamin D. The duration of the trials ranged from 1 year to 4
years, and the patients were predominately from Europe and
North America.
The enrolled patients were postmenopausal women with low
bone mass. Included patients were 45 years or older; the mean
average age per study was 69 years and ranged from 63 to 78
years. Note that the mean age for the subgroup with a FRAX score
of 20% or more in the bazedoxifene trial is higher than the mean
age for the full trial population (73 years vs. 66 years). Other
baseline clinical risk factors of interest such as body mass index,
bone mineral density, and presence of a baseline vertebral
fracture were not consistently reported across the trials.a
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Comparison based on AD of bisphosphonates and subgroup
with a FRAX score of 20% or more for bazedoxifene
Nine identiﬁed bisphosphonate RCTs had a similar (i.e., not
statistically signiﬁcant difference at the 0.05 level) nonvertebral
fracture incidence in the placebo arm as did the placebo response
of the subgroup with a FRAX score of 20% or more in the
bazedoxifene trial and hence were included in this analysis
[20–29]. The results of the analysis are provided in Table 2 and
suggest that bazedoxifene and risedronate are expected to be
more efﬁcacious than placebo in the higher risk population.
Alendronate and ibandronate are expected to be comparable
with placebo; the point estimates favor alendronate but not
ibandronate over placebo in this population. Overall, bazedox-
ifene shows comparable reductions in nonvertebral fracture risk
as do oral bisphosphonates although it has a larger reduction in
risk than does ibandronate and more than 90% probability of
being better than each of the oral bisphosphonates in the higher
risk population. For the higher risk population, there is a 90%
probability that bazedoxifene will provide the greatest nonverte-
bral fracture risk reduction of the ﬁve interventions compared.
The expected proportion of patients experiencing a nonvertebral
fracture for each intervention is presented in Figure 2 to facilitate
comparisons.T
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anMeta-regression based on AD of bisphosphonates and all FRAX
subgroups for bazedoxifene
Data from each of the eight FRAX subgroups in the bazedoxifene
trial were combined with all the bisphosphonate AD with cova-
riates to capture the impact of placebo response on the treatment
effects (i.e., log OR of nonvertebral fractures) with each inter-
vention relative to placebo. The meta-regression model with
placebo response as a covariate indicates that alendronate,
risedronate, and bazedoxifene are more efﬁcacious than placebo
while ibandronate is comparable to placebo in the higher risk
population (Table 2). Overall, bazedoxifene is comparable to the
oral bisphosphonates although the point estimates favor baze-
doxifene; bazedoxifene has at least a 95% probability of being
better than each of the oral bisphosphonates in this population.
Fig. 2 – Modeled probability of a nonvertebral fracture (along with 95% credible interval) for each treatment. Analysis 1:
Unadjusted Comparison based on AD of bisphosphonates and FRAX > = 20% subgroup for bazedoxifene (N = 24,058);
Analysis 2: Meta-regression controlling for baseline risk (placebo response) based on AD of bisphosphonates and all FRAX
subgroups for bazedoxifene (N = 29,267); Analysis 3: Meta-regression controlling for baseline risk (placebo response in
bisphosphonate trials and FRAX for bazedoxiﬁne trial) based on AD of bisphosphonates and IPD for bazedoxifene (N = 29,267).
The treatment effects were centered at a 10-year fracture risk > = 20%. FRAX, Fracture Risk Assessment Tool.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 2 4 – 4 3 2430Meta-regression based on AD of bisphosphonates and IPD for
bazedoxifene
The results of the meta-regression adjusting for placebo response
in the bisphosphonate trials and the FRAX score in the bazedox-
ifene trial also suggest that bazedoxifene is comparable to
the oral bisphosphonates in the higher risk population. Although
the point estimates favor bazedoxifene, there is considerable
uncertainty associated with the estimates. Bazedoxifene has a
70% probability of being the best intervention compared.Discussion
This study compared bazedoxifene with oral bisphosphonates for
the prevention of nonvertebral fractures in postmenopausal
women who are at a higher risk of fracture. To provide compa-
rative evidence on nonvertebral fractures for bazedoxifene versus
bisphosphonates for this population, an NMA was performed.
When considering only those bisphosphonate trials that reported
a placebo nonvertebral fracture response similar to the placebo
response of the subgroup with a FRAX score of 20% or more from
the bazedoxifene trial, bazedoxifene has at least comparable RRR
of non-vertebral fractures as the oral bisphosphonates. This
ﬁnding was conﬁrmed by analyses in which treatment effects
with bisphosphonates were projected to a population with a
FRAX score of 20% or more with a meta-regression approach
based on all data from all trials in the NMA.
The currently available RCTs did not provide treatment
effect estimates of bazedoxifene versus bisphosphonates for
the prevention of nonvertebral fractures. Although a meta-
analysis has been performed to assess the effect of several
osteoporosis treatments including bisphosphonates on the
risk of nonvertebral fractures, the study did not include bazedox-
ifene [17]. Furthermore, the meta-analysis did not provide com-
parative estimates for the subgroup of women at a higher risk of
fracture.Randomization of patients holds only within an RCT but not
across RCTs, and consequently there may be systematic differ-
ences in study and/or patient characteristics across the RCTs that
are modiﬁers of the treatment effects, which may bias the results.
In all the analyses presented here, the similarity across compar-
isons was based on the placebo risk of nonvertebral fractures,
which reﬂects the prognostic effect of all study and patient
characteristics on the occurrence of nonvertebral fractures. By
doing so, all variables that are both prognostic factors and
treatment effect modiﬁers are implicitly captured. The only
variables that we did not adjust for by using the placebo risk
are variables that are treatment effect modiﬁers but not prog-
nostic factors of the nonvertebral fracture risk. We consider this,
however, to be a minor source of possible bias in the indirect
comparison.
The ﬁrst analysis in this study incorporated the evidence from
bisphosphonate trials with a placebo response similar to that of
the subgroup with a FRAX score of 20% or more in the bazedox-
ifene trial. To evaluate the sensitivity of the ﬁndings, a second
analysis was conducted in which a linear relationship between
baseline risk and treatment effects was estimated on the basis of
data from all identiﬁed trials and all subgroups from the baze-
doxifene trial. In a third analysis, IPD was used to model the
relationship between baseline severity (as measured with the
FRAX score) and treatment effects with bazedoxifene. Given that
subjects with a FRAX score of 20% or more account for
approximately 13% of the trial population, the effect of this
population on the slope of the linear regression across the
range of FRAX scores in an IPD analysis was not as great as
with the subgroup data and as such, the treatment effect
predicted for the population with a FRAX score of 20% or more
underestimated the observed treatment effect (results not pre-
sented). Given the power of the IPD, however, a nonlinear
relationship was modeled with an additional parameter that
provided a better ﬁt to the data. These results are presented in
analysis 3 of this study and are similar to the results from the
ﬁrst two analyses.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 2 4 – 4 3 2 431The ﬁndings from this study are relevant to the management
of patient care for those patients with a higher risk of non-
vertebral fractures. By incorporating all relevant RCT evidence
identiﬁed from a systematic literature review, this study allows
for the comparison of all active interventions despite the lack of
head-to-head RCT evidence. Furthermore, the methods used
allow for treatment comparisons pertaining to speciﬁc popula-
tions of interest that currently have not been studied in RCTs (e.
g., subgroup with a FRAX score of Z20%). Although results
pertaining to the overall population have important implications,
clinicians are also faced with individual patients with differing
baseline risks and hence results for subgroups may also aid
decisions.
Furthermore, the methods used in this study allow for
the probabilistic interpretation of results (e.g., the probability
of an intervention being better than another and the probability
of being the best intervention). With ﬁve interventions
being compared, there is a 20% chance of any one intervention
being the best in the absence of evidence. The results from
the analysis, however, suggest that there is at least a 70%
chance of bazedoxifene being the best intervention for the
population with a FRAX score of 20% or more. In other words,
there is a 70% probability that bazedoxifene provides the greatest
reduction in the risk of a nonvertebral fracture for a postmeno-
pausal woman with osteoporosis and a FRAX score of 20%
or more.
Several limitations of our study should be mentioned. First,
the analyses are based on aggregated published data for the oral
bisphosphonates because access to IPD was not available; sub-
group data based on FRAX and IPD were available only for the
bazedoxifene trial. Consequently, a nonlinear relationship
between baseline risk and treatment effects could be modeled
only for bazedoxifene while a linear relationship was assumed
for the bisphosphonates given the limited data. Second, the
current study is limited to nonvertebral fractures. Vertebral
fractures are also associated with high morbidity and health care
costs, and additional analysis on vertebral fractures should be
warranted in the future to have a complete model of all osteo-
porotic fractures. Furthermore, analyses of adverse events should
be considered given concerns over the safety of treatments for
osteoporosis. In addition, non-English studies were excluded and
the potential for language bias should be considered. Finally, only
published studies were included from the literature review and
no attempt was made to contact investigators regarding the
presence of negative results. Hence, there is potential for
publication bias.
In conclusion, based on the currently available RCT evi-
dence, bazedoxifene showed at least a comparable risk reduc-
tion in nonvertebral fractures as did alendronate, ibandronate,
and risedronate in postmenopausal women with osteoporosis
with an elevated FRAX score. Our study suggests that bazedox-
ifene is likely to be at least as effective as oral bisphospho-
nates for the prevention of nonvertebral fractures in
postmenopausal women with osteoporosis who are at a higher
risk of fracture [18].
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